NCT06782074

Brief Summary

The primary goal of the study is to explore the neurocognitive, emotional-behavioral functioning, and quality of life of adolescents with IGE, identifying key factors that affect their overall well-being. The study involves participants and their caregivers completing standardized questionnaires. Additionally, clinical and anamnesic information will be collected to investigate the role of these variables on the emotional and executive functioning of the enrolled subjects

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
96

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jun 2023

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2023

Completed
1.5 years until next milestone

First Submitted

Initial submission to the registry

December 6, 2024

Completed
1 month until next milestone

First Posted

Study publicly available on registry

January 17, 2025

Completed
13 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 30, 2025

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2025

Completed
Last Updated

January 17, 2025

Status Verified

January 1, 2025

Enrollment Period

1.7 years

First QC Date

December 6, 2024

Last Update Submit

January 13, 2025

Conditions

Outcome Measures

Primary Outcomes (4)

  • cognition in patients with IGE throughout standardized tool WISC IV Wechsler Intelligence Scale for Children - Fourth Edition) or WAIS IV Wechsler Adult Intelligence Scale

    The study includes the administration of standardized tool (WISC IV or WAIS IV) to describe the cognitive profile of these patients . Minimum score 40 max 160, average score 100, higher scores mean a better performance

    1 year

  • quality of life in patients with IGE throughout standardized questionnaire

    The study wants to describe quality of life in patients with IGE using standardized questionaire Pediatric Quality of Life Inventory (PedsQL)epilepsy module (min score 0, max 100; higher scores reflect a better quality of life).

    1 year

  • behavioral profile in patients with IGE throughout standardized questionnaire

    The study aims to define the behavioral profile of patients with IGE using standardized questionnaire: Child Behavior Checklist CBCL (min 0 max 200 higher score worse emotional profile) ,SAFA Strumenti di Autovalutazione per Fanciulli e Adolescenti (Self-Assessment Tools for Children and Adolescents (score min 0 max 100 Higher scores indicate greater emotional or behavioral difficulties.

    1 year

  • executive profile of patients with IGE using standardized questionnaire BRIEF 2

    The study aims to define the executive profile of patients with IGE using standardized questionnaire Behavior Rating Inventory of Executive Function, Second Edition BRIEF 2 (score min 0 max 160 Higher scores indicate greater executive function difficulties.)

    1 year

Secondary Outcomes (1)

  • correlation between presence of neurodevelopmental comorbilities and quality of life using an ad hoc questionnaire

    1 year

Other Outcomes (2)

  • correlation between seizure frequency and qol using an ad hoc questionnaire

    1 year

  • correlation between the use of antiseizure medication and quality of life using a standardized questionnaire

    1 year

Interventions

The tests for evaluating emotional-behavioral functioning and quality of life will be self-administered by the patient/caregiver during regular follow-up visits. The cognitive assessment will be conducted by the clinician using standardized tests.

Eligibility Criteria

Age11 Years - 17 Years
Sexall
Age GroupsChild (0-17)
Sampling MethodNon-Probability Sample
Study Population

All patients attending the participating clinical units during the 2-year study period will be included in the study.

You may qualify if:

  • Age between 11 and 18 years Diagnosis of idiopathic generalized epilepsy

You may not qualify if:

  • Age under 11 years or over 18 years Structural or cryptogenic epilepsy Intellectual disability or borderline cognitive level Refusal to participate in the study Failure to obtain informed consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Clinical Trial Center

Pavia, 27100, Italy

RECRUITING

MeSH Terms

Conditions

Epilepsy

Interventions

Neuropsychological Tests

Condition Hierarchy (Ancestors)

Brain DiseasesCentral Nervous System DiseasesNervous System Diseases

Intervention Hierarchy (Ancestors)

Psychological TestsBehavioral Disciplines and Activities

Central Study Contacts

Valentina De Giorgis, MD PhD

CONTACT

martina paola P. zanaboni, psy

CONTACT

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 6, 2024

First Posted

January 17, 2025

Study Start

June 1, 2023

Primary Completion

January 30, 2025

Study Completion

June 30, 2025

Last Updated

January 17, 2025

Record last verified: 2025-01

Data Sharing

IPD Sharing
Will not share

Locations